Last reviewed · How we verify
taxol plus everolimus
taxol plus everolimus is a Small molecule drug developed by Samsung Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | taxol plus everolimus |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions (NA)
- EVERO Drug-coated Balloon (DCB) Randomized Trial (NA)
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model (PHASE3)
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (PHASE1)
- Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions (NA)
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (PHASE1, PHASE2)
- Bingo Drug-eluting Balloon Versus a Drug-eluting Stent for Coronary Bifurcation Lesions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- taxol plus everolimus CI brief — competitive landscape report
- taxol plus everolimus updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about taxol plus everolimus
What is taxol plus everolimus?
taxol plus everolimus is a Small molecule drug developed by Samsung Medical Center.
Who makes taxol plus everolimus?
taxol plus everolimus is developed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).
What development phase is taxol plus everolimus in?
taxol plus everolimus is in Phase 1.
Related
- Manufacturer: Samsung Medical Center — full pipeline
- Compare: taxol plus everolimus vs similar drugs
- Pricing: taxol plus everolimus cost, discount & access